Gilotrif afatinib regulatory update

FDA approved an sNDA from Boehringer for Gilotrif afatinib to treat metastatic, squamous non-small cell lung cancer (NSCLC) progressing after platinum-based chemotherapy. Gilotrif is marketed in the U...